161 related articles for article (PubMed ID: 28653941)
1. Transient thyrotoxicosis during nivolumab treatment.
van Kooten MJ; van den Berg G; Glaudemans AWJM; Hiltermann TJN; Groen HJM; Rutgers A; Links TP
Neth J Med; 2017 Jun; 75(5):204-207. PubMed ID: 28653941
[TBL] [Abstract][Full Text] [Related]
2. Clinical Features of Nivolumab-Induced Thyroiditis: A Case Series Study.
Yamauchi I; Sakane Y; Fukuda Y; Fujii T; Taura D; Hirata M; Hirota K; Ueda Y; Kanai Y; Yamashita Y; Kondo E; Sone M; Yasoda A; Inagaki N
Thyroid; 2017 Jul; 27(7):894-901. PubMed ID: 28537531
[TBL] [Abstract][Full Text] [Related]
3. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer.
Brahmer J; Reckamp KL; Baas P; Crinò L; Eberhardt WE; Poddubskaya E; Antonia S; Pluzanski A; Vokes EE; Holgado E; Waterhouse D; Ready N; Gainor J; Arén Frontera O; Havel L; Steins M; Garassino MC; Aerts JG; Domine M; Paz-Ares L; Reck M; Baudelet C; Harbison CT; Lestini B; Spigel DR
N Engl J Med; 2015 Jul; 373(2):123-35. PubMed ID: 26028407
[TBL] [Abstract][Full Text] [Related]
4. Induction of painless thyroiditis in patients receiving programmed death 1 receptor immunotherapy for metastatic malignancies.
Orlov S; Salari F; Kashat L; Walfish PG
J Clin Endocrinol Metab; 2015 May; 100(5):1738-41. PubMed ID: 25751110
[TBL] [Abstract][Full Text] [Related]
5. Nivolumab causing painless thyroiditis in a patient with adenocarcinoma of the lung.
Verma I; Modi A; Tripathi H; Agrawal A
BMJ Case Rep; 2016 Jan; 2016():. PubMed ID: 26733436
[TBL] [Abstract][Full Text] [Related]
6. Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer.
Mahjoubi L; Gazzah A; Marabelle A; Le Roy Ladurie F; Lambotte O; Caramella C; Adam J; Besse B; Soria JC
Eur J Cancer; 2017 Nov; 85():155-157. PubMed ID: 28917814
[No Abstract] [Full Text] [Related]
7. Lung Tissue Injury as an Atypical Response to Nivolumab in Non-Small Cell Lung Cancer.
Rampinelli C; Spitaleri G; Passaro A; Pochesci A; Ancona E; De Marinis F
Am J Respir Crit Care Med; 2017 Nov; 196(10):1349-1350. PubMed ID: 28910131
[No Abstract] [Full Text] [Related]
8. Nivolumab: a review in advanced squamous non-small cell lung cancer.
Keating GM
Drugs; 2015 Nov; 75(16):1925-34. PubMed ID: 26514815
[TBL] [Abstract][Full Text] [Related]
9. Long-Lasting Response to Nivolumab and Immune-Related Adverse Events in a Nonsquamous Metastatic Non-Small Cell Lung Cancer Patient.
Ricciuti B; Metro G; Baglivo S; Colabrese D; Chiari R; Bennati C; Paglialunga L
J Thorac Oncol; 2017 May; 12(5):e51-e55. PubMed ID: 28434516
[No Abstract] [Full Text] [Related]
10. Nivolumab-associated nausea and vomiting as an immune adverse event.
Shi Y; Lin P; Ho EY; Nock CJ
Eur J Cancer; 2017 Oct; 84():367-369. PubMed ID: 28827043
[No Abstract] [Full Text] [Related]
11. Risk of tumor flare after nivolumab treatment in patients with irradiated field recurrence.
Yoshida T; Furuta H; Hida T
Med Oncol; 2017 Mar; 34(3):34. PubMed ID: 28138869
[TBL] [Abstract][Full Text] [Related]
12. Severe exacerbation or manifestation of primary disease related to nivolumab in non-small-cell lung cancer patients with poor performance status or brain metastases.
Kanai O; Fujita K; Okamura M; Nakatani K; Mio T
Ann Oncol; 2016 Jul; 27(7):1354-6. PubMed ID: 27037297
[No Abstract] [Full Text] [Related]
13. Nivolumab-Induced Recurrence of Rheumatoid Arthritis in a Patient With Advanced Non-Small Cell Lung Cancer: A Case Report.
Syrigos K; Tsagouli S; Grapsa D
Ann Intern Med; 2016 Dec; 165(12):894-895. PubMed ID: 27992901
[No Abstract] [Full Text] [Related]
14. Nivolumab induced myxedema crisis.
Khan U; Rizvi H; Sano D; Chiu J; Hadid T
J Immunother Cancer; 2017; 5():13. PubMed ID: 28239466
[TBL] [Abstract][Full Text] [Related]
15. A case of de novo palmoplantar psoriasis with psoriatic arthritis and autoimmune hypothyroidism after receiving nivolumab therapy.
Elosua-González M; Pampín-Franco A; Mazzucchelli-Esteban R; Mielgo-Rubio X; Rodriguez-Vásquez X; García-Zamora E; López-Estebaranz JL
Dermatol Online J; 2017 Aug; 23(8):. PubMed ID: 29469753
[TBL] [Abstract][Full Text] [Related]
16. [Psoriasis and Psoriatic Arthritis Induced by Nivolumab in a Patient with Advanced Non-Small-Cell Lung Cancer].
Sugiura Y; Fujimoto H; Yamamoto M; Nomura H; Hashizume T; Kawai O; Araki N; Kawakami K; Sueki H; Fusegawa H; Ohkubo Y; Nemoto E
Gan To Kagaku Ryoho; 2017 Sep; 44(9):787-789. PubMed ID: 28912410
[TBL] [Abstract][Full Text] [Related]
17. Use of the PD-1 Pathway Inhibitor Nivolumab in a Renal Transplant Patient With Malignancy.
Boils CL; Aljadir DN; Cantafio AW
Am J Transplant; 2016 Aug; 16(8):2496-7. PubMed ID: 26988410
[No Abstract] [Full Text] [Related]
18. Corneal graft rejection in a patient treated with nivolumab for primary lung cancer.
Le Fournis S; Gohier P; Urban T; Jeanfaivre T; Hureaux J
Lung Cancer; 2016 Dec; 102():28-29. PubMed ID: 27987584
[TBL] [Abstract][Full Text] [Related]
19. Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial.
Rizvi NA; Mazières J; Planchard D; Stinchcombe TE; Dy GK; Antonia SJ; Horn L; Lena H; Minenza E; Mennecier B; Otterson GA; Campos LT; Gandara DR; Levy BP; Nair SG; Zalcman G; Wolf J; Souquet PJ; Baldini E; Cappuzzo F; Chouaid C; Dowlati A; Sanborn R; Lopez-Chavez A; Grohe C; Huber RM; Harbison CT; Baudelet C; Lestini BJ; Ramalingam SS
Lancet Oncol; 2015 Mar; 16(3):257-65. PubMed ID: 25704439
[TBL] [Abstract][Full Text] [Related]
20. Delayed Presentation of Isolated Adrenocorticotropin Insufficiency after Nivolumab Therapy for Advanced Non-small-cell lung carcinoma (NSCLC).
Shrotriya S; Rai MP; Alratroot A; Sarzynski E
BMJ Case Rep; 2018 Aug; 2018():. PubMed ID: 30093497
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
